90. 網膜色素変性症 ［臨床試験数：78，薬物数：104（DrugBank：36），標的遺伝子数：50，標的パスウェイ数：112］
Searched query = "Retinitis pigmentosa", "Rod dystrophy", "Rod Cone Dystrophy"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04120883 | January 2020 | 4 November 2019 | Oral Hydroxychloroquine (HCQ) for Retinitis Pigmentosa Caused by P23H- Rhodopsin (RHO) | Oral Hydroxychloroquine for Retinitis Pigmentosa Caused by P23H-RHO (Substitution of Proline to Histidine at Codon 23 of the Rhodopsin Protein) | Retinitis Pigmentosa | Drug: Hydroxychloroquine lower dose;Drug: Hydroxychloroquine higher dose | University of Michigan | Cures Within Reach | Not recruiting | 18 Years | N/A | All | 12 | Phase 1/Phase 2 | United States |
| 2 | NCT02018692 | December 1, 2019 | 4 March 2019 | The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa | The Effect of Oral Administration of 9-cis ß Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | Dietary Supplement: Alga Dunaliella Bardawil powder;Dietary Supplement: Placebo:Starch | Sheba Medical Center | Not recruiting | 12 Years | 18 Years | All | 30 | Phase 1/Phase 2 | Israel | |
| 3 | NCT04123626 | October 7, 2019 | 22 October 2019 | A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene | A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene | Autosomal Dominant Retinitis Pigmentosa;Eye Diseases;Eye Diseases, Hereditary;Retinal Dystrophies;Retinal Disease;Retinitis;Vision Tunnel;Vision Disorders | Drug: QR-1123;Other: Sham procedure | ProQR Therapeutics | Recruiting | 18 Years | N/A | All | 35 | Phase 1/Phase 2 | United States | |
| 4 | NCT04068207 | September 23, 2019 | 7 October 2019 | Minocycline Treatment in Retinitis Pigmentosa | The Efficacy and Safety of Oral Minocycline in the Treatment of Retinitis Pigmentosa: An Open-label Clinical Trial | Retinitis Pigmentosa;Inherited Retinal Dystrophy;Retina Disorder | Drug: Minocycline | Sun Yat-sen University | Recruiting | 18 Years | 60 Years | All | 35 | Phase 2 | China | |
| 5 | NCT03963154 | August 19, 2019 | 14 October 2019 | Interventional Study of Implantation of hESC-derived RPE in Patients With RP Due to Monogenic Mutation | STREAM: A Phase 1/2, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Implantation Into One Eye of hESC-derived RPE in Patients With Retinitis Pigmentosa Due to Monogenic Mutation | Retinitis Pigmentosa | Biological: Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE) | Centre d'Etude des Cellules Souches | Recruiting | 18 Years | 65 Years | All | 12 | Phase 1/Phase 2 | France | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | NCT03999021 | June 24, 2019 | 15 July 2019 | FIGHT-RP 1 Extension Study | A Phase 1 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: NAC effervescent tablets | Johns Hopkins University | Recruiting | 18 Years | N/A | All | 30 | Phase 1 | United States | |
| 7 | NCT03944239 | June 2019 | 20 May 2019 | Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa | Safety and Efficacy of Subretinal Transplantation of Clinical Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Retinitis Pigmentosa | Retinitis Pigmentosa | Biological: Retinal pigment epitheliums transplantation | Qi Zhou | Beijing Tongren Hospital | Recruiting | 18 Years | 80 Years | All | 10 | Phase 1 | China |
| 8 | NCT03780257 | March 6, 2019 | 4 November 2019 | Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene | A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene | Retinitis Pigmentosa;Usher Syndrome Type 2;Deaf Blind;Retinal Disease;Eye Diseases;Eye Diseases, Hereditary;Eye Disorders Congenital;Vision Disorders | Drug: QR-421a;Other: Sham-procedure | ProQR Therapeutics | Recruiting | 18 Years | N/A | All | 18 | Phase 1/Phase 2 | United States;Belgium;Canada;France | |
| 9 | JPRN-jRCT2051180072 | 01/03/2019 | 2 April 2019 | Clinical trial of TK-98 on retinitis pigmentosa: A prospective, randomized, double-blind, placebo-controlled study | Clinical trial of TK-98 on retinitis pigmentosa: A prospective, randomized, double-blind, placebo-controlled study - Clinical trial of TK-98 on retinitis pigmentosa | retinitis pigmentosa retinitis pigmentosa;retinitis pigmentosa | Investigational drug (TK-99 or placebo) administration: one packet after every meal (thrice a day);branched-chain amino acids | Hanako Ikeda | Recruiting | 20 years | No maximum age-limit | Both | 70 | Phase 2 | none | |
| 10 | EUCTR2018-002433-38-FR | 15/02/2019 | 30 April 2019 | Study to evaluate QR-421a in subjects with retinitis pigmentosa (RP) due to mutations in exon 13 of the USH2A Gene | A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene - STELLAR | Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene MedDRA version: 20.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: QR-421a Product Code: QR-421a Pharmaceutical Form: Solution for injection INN or Proposed INN: Not available Current Sponsor code: QR-421a Other descriptive name: QR-421a Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 15- | ProQR Therapeutics | Authorised | Female: yes Male: yes | 18 | Phase 1;Phase 2 | United States;France;Canada;Belgium | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | EUCTR2013-005393-22-NL | 04/01/2019 | 28 February 2019 | A study in subjects with rare inherited eye conditions caused by gene mutations to see if treatment with QLT091001 is safe and works to improve subjects' vision. | A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) | Inherited retinal disease (IRD) phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by mutations in the retinal pigment epithelium protein 65 (RPE65) or lecithin:retinol acyltransferase (LRAT) genes MedDRA version: 19.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 19.0 Level: PT Classification code 10070667 Term: Leber's congenital amaurosis System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: QLT091001 Product Code: QLT091001 Pharmaceutical Form: Oral solution INN or Proposed INN: Zuretinol Acetate Other descriptive name: QLT091001 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | QLT Inc. | Not Available | Female: yes Male: yes | 48 | Phase 3 | France;United States;Canada;Brazil;Denmark;Germany;Netherlands;United Kingdom;Switzerland | |||
| 12 | NCT03772938 | December 13, 2018 | 18 December 2018 | Stem Cells Therapy in Degenerative Diseases of the Retina | Stem Cells Therapy in Degenerative Diseases of the Retina | Retinal Degeneration;Retinitis Pigmentosa;Age Related Macular Degeneration;Stargardt Disease 1 | Biological: Stem/progenitor cells transplantation | Pomeranian Medical University Szczecin | Recruiting | 18 Years | 65 Years | All | 30 | Phase 1 | Poland | |
| 13 | NCT03078309 | September 2018 | 20 August 2018 | The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients | A Controlled Study of the Effect of Cannabis on Visual Functions in Healthy Subjects and in Retinitis Pigmentosa Patients | Retinitis Pigmentosa;Retinal Degeneration;Cannabis | Drug: cannabis | Hadassah Medical Organization | Hebrew University of Jerusalem | Recruiting | 18 Years | 70 Years | All | 50 | Early Phase 1 | Israel |
| 14 | NCT03374657 | August 22, 2018 | 7 October 2019 | A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa | An Open-label First-in-human Single Ascending Dose Study to Explore Safety, Tolerability and Efficacy of Subretinal Administration of CPK850 Gene Therapy in Patients With Retinitis Pigmentosa Due to Mutations in the Retinaldehyde Binding Protein 1 (RLBP1) Gene | Retinitis Pigmentosa | Biological: CPK850 | Novartis Pharmaceuticals | Recruiting | 18 Years | 70 Years | All | 21 | Phase 1/Phase 2 | Sweden | |
| 15 | NCT03566147 | August 1, 2018 | 20 August 2018 | Treatment of RP and LCA by Primary RPE Transplantation | Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis by Primary Retinal Pigment Epithelial Cells Transplantation | Leber Congenital Amaurosis, Retinitis Pigmentosa | Biological: Human primary Retinal Pigment Epithelial (HuRPE) cells | Eyecure Therapeutics Inc. | Beijing Tongren Hospital | Recruiting | 18 Years | 70 Years | All | 30 | Early Phase 1 | China |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT03316560 | April 16, 2018 | 3 June 2019 | Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations | An Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations | X-Linked Retinitis Pigmentosa | Biological: rAAV2tYF-GRK1-RPGR | Applied Genetic Technologies Corp | Recruiting | 6 Years | N/A | Male | 30 | Phase 1/Phase 2 | United States | |
| 17 | NCT03328130 | November 6, 2017 | 22 July 2019 | Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene | Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression | Retinitis Pigmentosa | Biological: AAV2/5-hPDE6B | Horama S.A. | Recruiting | 18 Years | N/A | All | 15 | Phase 1/Phase 2 | France | |
| 18 | EUCTR2016-001429-16-FR | 28/07/2017 | 16 October 2017 | Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression. | Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients Harboring Mutations in the PDE6B Gene Leading to a Defect in PDE6B Expression. | Retinitis Pigmentosa;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Code: HORA-PDE6B (AAV2/5.hPDE6B) Pharmaceutical Form: Solution for injection | HORAMA SA | Authorised | Female: yes Male: yes | Phase 1;Phase 2 | France | ||||
| 19 | EUCTR2016-003967-21-GB | 09/06/2017 | 11 December 2017 | Gene Therapy Trial for People with Retinitis Pigmentosa (progressive reduction in vision) due to a gene defect on Chromosome X. | An open label, multi-centre, Phase I/II dose escalation trial of a recombinant adeno-associated virus vector (AAV2/5-hRKp.RPGR) for gene therapy of adults and children with X-linked Retinitis Pigmentosa owing to defects in Retinitis Pigmentosa GTPase Regulator (RPGR) - Gene Therapy Trial for People with Retinitis Pigmentosa: RPGR | X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene MedDRA version: 20.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: AAV2/5-hRKp.RPGR Pharmaceutical Form: Solution for injection INN or Proposed INN: AAV2/5-hRKp.RPGR Current Sponsor code: AAV2/5-hRKp.RPGR Concentration unit: billion organisms/ml billion organisms/millilitre Concentration type: up to Concentration number: 1000- | MeiraGTx UK II Limited | Authorised | Female: no Male: yes | 36 | Phase 1;Phase 2 | United Kingdom;United States | |||
| 20 | NCT03116113 | March 16, 2017 | 2 September 2019 | A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa | A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) | X-Linked Retinitis Pigmentosa | Biological: AAV8-RPGR | NightstaRx Ltd | Recruiting | 10 Years | N/A | Male | 63 | Phase 2/Phase 3 | United States;United Kingdom | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 21 | NCT03073733 | March 1, 2017 | 18 March 2019 | Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa | A Prospective, Multicenter, Randomized, Study of the Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP) | Retinitis Pigmentosa | Biological: human retinal progenitor cells;Other: Mock injection | jCyte, Inc | California Institute for Regenerative Medicine (CIRM) | Not recruiting | 18 Years | N/A | All | 84 | Phase 2 | United States |
| 22 | NCT03063021 | February 15, 2017 | 25 March 2019 | The FIGHT-RP1 Study | A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study) | Retinitis Pigmentosa | Drug: N-Acetyl Cysteine (NAC) | Johns Hopkins University | Not recruiting | 18 Years | N/A | All | 30 | Phase 1 | United States | |
| 23 | EUCTR2016-003852-60-GB | 09/01/2017 | 7 January 2019 | A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa using AAV8 | A Dose Escalation (Phase 1), and Dose Expansion (Phase 2/3) Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV8) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR) - XIRIUS Study | X-Linked retinitis pigmentosa (XLRP) MedDRA version: 20.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: AAV8-RPGR Product Code: AAV8-RPGR Pharmaceutical Form: Suspension for injection | NightstaRx Limited | Authorised | Female: no Male: yes | 63 | Phase 1;Phase 2;Phase 3 | United States;United Kingdom | |||
| 24 | EUCTR2013-005393-22-DK | 03/11/2016 | 12 December 2016 | A study in subjects with rare inherited eye conditions caused by gene mutations to see if treatment with QLT091001 is safe and works to improve subjects' vision. | A Study of the Efficacy and Safety of QLT091001 in Subjects with Inherited Retinal Disease (IRD) Caused by Mutation in Retinal Pigment Epithelium Protein 65 (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) | Inherited retinal disease (IRD) phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by mutations in the retinal pigment epithelium protein 65 (RPE65) or lecithin:retinol acyltransferase (LRAT) genes MedDRA version: 19.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders MedDRA version: 19.0 Level: PT Classification code 10070667 Term: Leber's congenital amaurosis System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: QLT091001 Product Code: QLT091001 Pharmaceutical Form: Oral solution INN or Proposed INN: Zuretinol Acetate Other descriptive name: QLT091001 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 20- Pharmaceutical form of the placebo: Oral solution Route of administration of the placebo: Oral use | QLT Inc. | Authorised | Female: yes Male: yes | 48 | Phase 3 | France;United States;Canada;Brazil;Denmark;Netherlands;Germany;United Kingdom;Switzerland | |||
| 25 | EUCTR2016-002523-28-GB | 16/09/2016 | 6 February 2017 | A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa. | A Pilot Study Evaluating the Effect of Intravitreal Fluocinolone Acetonide (0.19mg) in Patients with Retinitis Pigmentosa - Iluvien for IRD | Retinitis Pigmetosa. MedDRA version: 19.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Body processes [G] - Genetic Phenomena [G05] | Trade Name: Iluvien Product Name: Iluvien Product Code: n/a Pharmaceutical Form: Implant INN or Proposed INN: Fluocinolone Acetonide CAS Number: 67-73-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.19- | Moorfields Eye Hospital | Authorised | Female: yes Male: yes | Phase 2 | United Kingdom | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 26 | JPRN-UMIN000022686 | 2016/07/01 | 22 July 2019 | The Clinical Efficacy of Carbonic Anhydrase Inhibitors and Steroids in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa | The Clinical Efficacy of Carbonic Anhydrase Inhibitors and Steroids in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa - The Clinical Efficacy in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa | retinitis pigmentosa | 1% dorzolamide eye drop three times daily in each eye 0.1% betamethasone sodium phosphate eye drop three times daily in each eye oral 250mg acetazolamide two tablets daily 40mg triamcinolone acetonide into the sub-Tenon capsule | Kyushu University Hospital | Not Recruiting | 20years-old | Not applicable | Male and Female | 40 | Not applicable | Japan | |
| 27 | NCT02837640 | June 2016 | 8 August 2016 | Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa | The Effect of L-Dopa on the Progression of Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: levodopa-carbidopa | Beirut Eye Specialist Hospital | Recruiting | 10 Years | 65 Years | Both | 50 | Phase 2 | Lebanon | |
| 28 | EUCTR2015-003723-65-GB | 12/01/2016 | 28 February 2019 | Prospective non-randomised pilot study looking at the safety and efficacy of a drug called Eylea for patients with an eye condition called Retinitis Pigmentosa, that also have swelling at the back of the eye | Aflibercept (Eylea®) for macular oedema associated with underlying Retinitis Pigmentosa (AMOUR) - AMOUR | Retinitis Pigmentosa associated Cystoid Macular Oedema MedDRA version: 18.1 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: Eylea Product Name: Eylea Product Code: n/a Pharmaceutical Form: Solution for injection INN or Proposed INN: Aflibercept CAS Number: 862111-32-8 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 40- | Moorfields Eye Hospital | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | United Kingdom | |||
| 29 | NCT02556736 | December 14, 2015 | 2 September 2019 | RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa | Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP) | Advanced Retinitis Pigmentosa | Drug: RST-001 | Allergan | Recruiting | 18 Years | N/A | All | 21 | Phase 1/Phase 2 | United States | |
| 30 | NCT02464436 | December 2015 | 4 March 2019 | Safety and Tolerability of hRPC in Retinitis Pigmentosa | First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP) | Retinitis Pigmentosa | Drug: hRPC | ReNeuron Limited | Recruiting | 18 Years | N/A | All | 21 | Phase 1/Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 31 | NCT02320812 | June 2015 | 18 March 2019 | Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa | A Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP) | Retinitis Pigmentosa (RP) | Biological: human retinal progenitor cells | jCyte, Inc | California Institute for Regenerative Medicine (CIRM) | Not recruiting | 18 Years | N/A | All | 28 | Phase 1/Phase 2 | United States |
| 32 | NCT02465749 | May 2015 | 29 June 2015 | Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa | Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Continuous oxygen;Device: blue light-absorbing sunglasses;Drug: Compound thrombosis capsule sig: 1.5g/tid;Drug: Ginkgo biloba pills sig: 300mg/tid;Drug: Vitamin B sig: 10mg/tid;Drug: Vitamin AD sig: 1 tablet/tid | Sun Yat-sen University | Zhujiang Hospital;Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;Guangzhou Jeeyor Medical Research Co.,Ltd. | Not recruiting | 18 Years | 60 Years | Both | 404 | Phase 0 | China |
| 33 | NCT02609165 | May 2015 | 16 December 2017 | Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema | Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial | Retinitis Pigmentosa;Cystoid Macular Edema | Drug: rhNGF 180 µg/ml eye drops solution;Drug: vehicle eye drops | Ospedale San Raffaele | Dompé Farmaceutici S.p.A | Not recruiting | 18 Years | N/A | All | 45 | Phase 2 | Italy |
| 34 | NCT02338973 | January 14, 2015 | 26 August 2019 | Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS) | Pilot Phase I/II Study of the Evaluation of Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS) | Inherited Ophthalmic Diseases;Inherited Retinal Degeneration | Drug: Interferon gamma-1b | National Eye Institute (NEI) | Not recruiting | 12 Years | N/A | All | 4 | Phase 1/Phase 2 | United States | |
| 35 | NCT02804360 | January 2015 | 27 June 2016 | Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study | Dexamethasone in Retinitis Pigmentosa Cystoid Macular Edema | Retinitis Pigmentosa;Cystoid Macular Edema | Device: dexamethasone injection | Rafic Hariri University Hospital | Recruiting | 16 Years | 90 Years | Both | 50 | Phase 2 | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 36 | NCT02244996 | November 2014 | 16 December 2017 | Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum | Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum | Retinitis Pigmentosa | Dietary Supplement: Lycium Barbarum;Dietary Supplement: Placebo | The Hong Kong Polytechnic University | The University of Hong Kong | Recruiting | 18 Years | 70 Years | All | 60 | Phase 2 | Hong Kong |
| 37 | NCT02280135 | November 2014 | 16 December 2017 | Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa | Phase I Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | Biological: Intravitreal injection of Autologous bone marrow Stem Cell;Other: Subconjunctival injection of saline | Red de Terapia Celular | Spanish National Health System;Hospital Universitario Virgen de la Arrixaca;Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia;Public Health Service, Murcia;Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca | Not recruiting | 18 Years | 70 Years | All | 8 | Phase 1 | Spain |
| 38 | EUCTR2014-000385-22-IT | 07/10/2014 | 23 March 2015 | Nerve Growth Factor eye drops as a novel treatment for patients with Retinitis Pigmentosa. | Nerve Growth Factor eye drops as a novel treatment for vision loss in patients with Retinitis Pigmentosa: from preclinical to clinical Phase II trial. - NEMO | Retinitis pigmentosa with cystoid macular edema MedDRA version: 17.0 Level: LLT Classification code 10054467 Term: Macular edema System Organ Class: 100000004853 MedDRA version: 17.0 Level: PT Classification code 10038914 Term: Retinitis pigmentosa System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Product Name: recombinant human Nerve Growth Factor (rhNGF) Pharmaceutical Form: Eye drops, solution INN or Proposed INN: not yet assigned Other descriptive name: RECOMBINANT HUMAN NERVE GROWTH FACTOR (RHNGF) Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.18- Pharmaceutical form of the placebo: Eye drops, solution Route of administration of the placebo: Ocular use | Ospedale San Raffaele di Milano | Authorised | Female: yes Male: yes | Phase 2 | Italy | ||||
| 39 | NCT01914913 | September 2014 | 19 February 2015 | Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa | An Open Labeled Clinical Study to Evaluate the Safety and Efficacy OF Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Retinitis Pigmentosa. It is Self Funded (Patients' Own Funding) Clinical Trial | Retinitis Pigmentosa | Biological: BMMNCs | Chaitanya Hospital, Pune | Recruiting | 18 Years | 65 Years | Both | 15 | Phase 1/Phase 2 | India | |
| 40 | NCT02140164 | May 2014 | 16 December 2017 | Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa | Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated With Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Minocycline | National Eye Institute (NEI) | The EMMES Corporation | Not recruiting | 12 Years | N/A | All | 7 | Phase 1/Phase 2 | United States |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 41 | NCT02709876 | April 2014 | 18 June 2018 | Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa | Retinitis Pigmentosa | Biological: Stem Cell Transplantation | Stem Cells Arabia | Not recruiting | 18 Years | 55 Years | All | 50 | Phase 1/Phase 2 | Jordan | ||
| 42 | NCT02110225 | January 2014 | 20 August 2018 | A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP) | A 24 Week Phase Ib/II, Multicenter, Randomized, Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up to Evaluate Safety and Potential Efficacy of 2 Doses (60, 180 µg/ml) of rhNGF Solution vs Vehicle in Patients With RP. | Retinitis Pigmentosa | Drug: rhNGF 60 µg/ml eye drops solution;Drug: rhNGF 180 µg/ml eye drops solution;Drug: Placebo | Dompé Farmaceutici S.p.A | Not recruiting | 18 Years | N/A | All | 50 | Phase 1/Phase 2 | Italy | |
| 43 | NCT01786395 | March 2013 | 8 February 2016 | Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa | Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period | Retinitis Pigmentosa | Drug: UF-021;Drug: Placebo | R-Tech Ueno, Ltd. | Not recruiting | 20 Years | 70 Years | Both | 202 | Phase 3 | Japan | |
| 44 | EUCTR2012-002436-82-ES | 13/12/2012 | 7 January 2013 | Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa | Melatonin effects on visual and sleep patterns anomalies in subjects diagnosed with Retinitis Pigmentosa | To evaluate the sleep quality in patients with Retinitis Pigmentosa;Therapeutic area: Diseases [C] - Eye Diseases [C11] | Trade Name: CIRCADIN 2 mg comprimidos de liberación prolongada Product Name: Circadin 2 mg Pharmaceutical Form: Prolonged-release tablet INN or Proposed INN: Not answered CAS Number: 73-31-4 Current Sponsor code: Not answered Other descriptive name: MELATONIN Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2- Pharmaceutical form of the placebo: Prolonged-release capsule Route of administration of the placebo: Oral use | Isabel Pinilla Lozano | Authorised | Female: yes Male: yes | Spain | |||||
| 45 | NCT01680510 | September 2012 | 4 March 2019 | The Effect of Oral Administration of 9-cis ß Carotene Rich Powder of the Alga Dunaliella Bardawil | The Effect of Oral Administration of 9-cis ß Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | Dietary Supplement: Alga Dunaliella Bardawil;Other: Placebo (starch) | Sheba Medical Center | Recruiting | 18 Years | N/A | All | 100 | Phase 2/Phase 3 | Israel | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 46 | NCT01736059 | July 2012 | 1 April 2019 | Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy | A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy | Non-exudative Age-related Macular Degeneration;Diabetic Retinopathy;Retina Vein Occlusion;Retinitis Pigmentosa;Hereditary Macular Degeneration | Drug: CD34+ bone marrow stem cells intravitreal | University of California, Davis | Recruiting | 18 Years | 100 Years | All | 15 | Phase 1 | United States | |
| 47 | NCT01543906 | February 2012 | 19 February 2015 | Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65) | An Open-Label, Phase 1b, Safety/Proof-of-Concept Study to Evaluate the Effects of Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65) | Retinitis Pigmentosa (RP) | Drug: QLT091001 | QLT Inc. | Not recruiting | 18 Years | 70 Years | Both | 5 | Phase 1 | Canada;Ireland | |
| 48 | NCT01521793 | January 2012 | 19 February 2015 | Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01) | An Open-Label Study to Evaluate the Effects of Repeated Treatments of Oral QLT091001 on Safety and Vision Outcome in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin: Retinol Acyltransferase (LRAT) (Extension of Study RET IRD 01) | LCA (Leber Congenital Amaurosis);RP (Retinitis Pigmentosa) | Drug: QLT091001 | QLT Inc. | Not recruiting | 5 Years | 65 Years | Both | 27 | Phase 1 | United States;Canada;Germany;Netherlands;United Kingdom | |
| 49 | NCT01530659 | January 2012 | 10 December 2018 | Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis Pigmentosa | Photoreceptor Structure in A Phase 2 Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Rates of Change in Cone Spacing and Density | Retinitis Pigmentosa;Usher Syndrome Type 2;Usher Syndrome Type 3 | Drug: NT-501;Procedure: Sham | Neurotech Pharmaceuticals | University of California, San Francisco;FDA Office of Orphan Products Development | Not recruiting | 18 Years | 55 Years | All | 30 | Phase 2 | United States |
| 50 | NCT01560715 | June 2011 | 16 December 2017 | Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa | Phase 2 Study Of Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa | Retinitis Pigmentosa | Biological: intravitreal injection of autologous bone marrow stem cells | University of Sao Paulo | Not recruiting | 18 Years | 75 Years | All | 50 | Phase 2 | Brazil | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 51 | NCT01399515 | March 2011 | 25 April 2016 | Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa | Retinitis Pigmentosa;Retinal Diseases;Eye Diseases;Eye Disease, Hereditary;Retinal Degeneration | Drug: Valproic Acid | Seoul National University Hospital | Not recruiting | 18 Years | N/A | Both | 200 | Phase 2 | Korea, Republic of | ||
| 52 | JPRN-JMA-IIA00053 | 24/12/2010 | 2 April 2019 | Clinical Trial of Therapeutic Effect of Valproic Acid in Retinitis Pigmentosa | Clinical Trial of Therapeutic Effect of Valproic Acid in Retinitis Pigmentosa | Retinitis Pigmentosa | Intervention type:DRUG. Intervention1:Sodium valproate, Dose form:TABLET, Route of administration:ORAL. | Yasuhiko Hirami | Masayo Takahashi, Yasuo Kurimoto | Not Recruiting | >=20 YEARS | No Limit | BOTH | 30 | NOT APPLICABLE | Japan |
| 53 | NCT01233609 | November 2010 | 16 December 2017 | Trial of Oral Valproic Acid for Retinitis Pigmentosa | A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Valproic Acid;Drug: Placebo | Foundation Fighting Blindness Clinical Research Institute | United States Department of Defense | Not recruiting | 18 Years | N/A | All | 90 | Phase 2 | United States |
| 54 | JPRN-UMIN000005852 | 2010/06/01 | 2 April 2019 | The Clinical Efficacy of a Topical Dorzolamide in the Management of Cystoid Macular Edema in Patients with Retinitis Pigmentosa | retinitis pigmentosa | 1% dorzolamide three times daily in each eye during the follow-up period | Kyushu university hospital | Not Recruiting | 20years-old | Not applicable | Male and Female | 20 | Not applicable | Japan | ||
| 55 | EUCTR2010-019079-32-PT | 19/05/2010 | 16 February 2015 | A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System | A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System | Patients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Retinitis pigmentosa) and 190342-032D (Geographic Atrophy from Age-related Macular Degeneration). | Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System Product Code: 9715X Pharmaceutical Form: Implant INN or Proposed INN: Brimonidine Tartrate CAS Number: 70359-46-5 Current Sponsor code: AGN 190342-LF Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 100- Pharmaceutical form of the placebo: Implant Route of administration of the placebo: Intravitreal use Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System Product Code: 9742X Pharmaceutical Form: Implant INN or Proposed INN: Brimonidine Tartrate CAS Number: 70359-46-5 Current Sponsor code: AGN 190342-LF Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Implant Route of administration of the placebo: Intravitreal use Product Name: Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimo PS DDS) Applicator System Product Code: 9741X Pharmaceutical Form: Implant INN or Proposed INN: Brimonidine Tartrate CAS Number: 70359-46-5 Current Sponsor code: AGN 190342-LF Concentration unit: µg microgram(s) Concentration type: equal Concentration number: 400- Pharmaceutical form of the placebo: Implant Route of administration of the placebo: Intravitreal use | Allergan Limited | Not Recruiting | Female: yes Male: yes | 290 | Portugal;Czech Republic;Germany;Italy;United Kingdom | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 56 | NCT01014052 | November 2009 | 19 February 2015 | Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) Mutations | Phase 1b Study to Evaluate QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Inherited Deficiencies of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) | LCA (Leber Congenital Amaurosis);RP (Retinitis Pigmentosa) | Drug: QLT091001 | QLT Inc. | Not recruiting | 5 Years | 65 Years | Both | 32 | Phase 1 | United States;Canada;Germany;Netherlands;United Kingdom | |
| 57 | EUCTR2008-004561-26-IT | 01/06/2009 | 19 March 2012 | Inner Retinal Dysfunction of the Cone System in Inherited Photoreceptor Degenerations: A Study of Disease Sequence and Assessment of Novel Therapeutic Strategies. - ND | Inner Retinal Dysfunction of the Cone System in Inherited Photoreceptor Degenerations: A Study of Disease Sequence and Assessment of Novel Therapeutic Strategies. - ND | retinitis pigmentosa MedDRA version: 9.1 Level: LLT Classification code 10038914 Term: Retinitis pigmentosa MedDRA version: 9.1 Level: PT Classification code 10038914 Term: Retinitis pigmentosa | Product Name: Nerve Growt Factor - 2.5S Pharmaceutical Form: Eye drops, solution CAS Number: 93928-24-6 Current Sponsor code: N 6009 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- Pharmaceutical form of the placebo: Eye drops, solution Route of administration of the placebo: Ocular use Pharmaceutical Form: Eye drops, solution INN or Proposed INN: COQUN Concentration unit: % percent Concentration type: equal Concentration number: .1- Pharmaceutical form of the placebo: Eye drops, solution Route of administration of the placebo: Ocular use | POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | Authorised | Female: yes Male: yes | Italy | |||||
| 58 | NCT01068561 | May 2009 | 19 February 2015 | Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa | Phase 1 Study Of Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa | Retinitis Pigmentosa | Biological: intravitreal injection of autologous bone marrow stem cells | University of Sao Paulo | Not recruiting | 18 Years | N/A | Both | 5 | Phase 1 | Brazil | |
| 59 | JPRN-UMIN000006820 | 2009/02/01 | 2 April 2019 | Neuroprotective efficacy of topical unoprostone isopropyl or nipradilol in patients with retinitis pigmentosa | retinitis pigmentosa | 0.12% topical unoprostone isopropyl twice daily 0.25% topical nipradilol twice daily | Kyushu university hospital | Not Recruiting | Not applicable | Not applicable | Male and Female | 50 | Not selected | Japan | ||
| 60 | NCT01773278 | December 2008 | 14 October 2019 | Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS) | Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS) | Smith-Lemli-Opitz Syndrome;Cone-Rod Dystrophy;Hearing Loss | Drug: Antioxidants;Drug: Cholesterol | University of Colorado, Denver | Recruiting | N/A | 65 Years | All | 100 | Phase 2 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 61 | JPRN-JapicCTI-090748 | 01/10/2008 | 23 April 2019 | Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosa | Phase II Study of 0.15% UF-021 in patients with retinitis pigmentosa | retinitis pigmentosa | Intervention name : UF-021 (isopropyl unoprostone) Dosage And administration of the intervention : Eye drop | R-Tech Ueno, Ltd | 20 | 65 | BOTH | 105 | Phase 2 | |||
| 62 | NCT01256697 | August 2008 | 19 February 2015 | The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions im Patients With Retinitis Pigmentosa | The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella | Retinitis Pigmentosa | Dietary Supplement: Alga Dunaliella Bardawil;Dietary Supplement: Alga Dunaliella Bardawill;Other: Sugar pill | Sheba Medical Center | Not recruiting | 18 Years | N/A | Female | 34 | N/A | Israel | |
| 63 | NCT00661479 | July 2008 | 19 October 2017 | An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: 400 µg Brimonidine Tartrate Implant;Drug: 200 µg Brimonidine Tartrate Implant;Drug: 100 µg Brimonidine Tartrate Implant;Other: Sham (no implant) | Allergan | Not recruiting | 18 Years | N/A | All | 21 | Phase 1/Phase 2 | United States;France;Germany;Portugal | ||
| 64 | NCT00458575 | April 2007 | 19 February 2015 | A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa | A Phase I Open Label Non-comparative Study Evaluating the Safety of a Single, Unilateral, Subretinal Administration of CNTO 2476 in Advanced Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: CNTO 2476 | Centocor, Inc. | Not recruiting | 18 Years | N/A | Both | 7 | Phase 1 | United States | |
| 65 | NCT00433277 | February 2007 | 19 February 2015 | Autoimmunity in Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: twice-daily dosage with 0.5% cyclosporine-A eyedrops | Semmelweis University | Not recruiting | N/A | N/A | Both | N/A | Hungary | |||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 66 | NCT00447980 | January 2007 | 28 November 2016 | A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis Pigmentosa | A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Field Sensitivity as the Primary Outcome | Retinitis Pigmentosa | Drug: NT-501 | Neurotech Pharmaceuticals | Not recruiting | 18 Years | 64 Years | Both | 68 | Phase 2 | United States | |
| 67 | NCT00447993 | January 2007 | 28 November 2016 | A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa | A Phase II/III Study of Encapsulated Human NTC-201 Cell Implants Releasing Ciliary Neurotrophic Factor (CNTF) for Participants With Retinitis Pigmentosa Using Visual Acuity as the Primary Outcome | Retinitis Pigmentosa | Drug: NT-501 | Neurotech Pharmaceuticals | Not recruiting | 18 Years | 68 Years | Both | 65 | Phase 2 | United States | |
| 68 | NCT00100230 | September 2004 | 19 October 2017 | DHA and X-Linked Retinitis Pigmentosa | Investigation of Effectiveness and Safety of High Dose Docosahexaenoic Acid (DHA) in X-Linked Retinitis Pigmentosa | Retinitis Pigmentosa;X-linked Genetic Diseases | Drug: docosahexaenoic acid OR corn/soy oil placebo | Retina Foundation of the Southwest | Foundation Fighting Blindness;DSM Nutritional Products, Inc. | Not recruiting | 7 Years | 32 Years | Male | 78 | Phase 2 | United States |
| 69 | NCT00461435 | January 2004 | 19 February 2015 | Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa | Slowing the Degenerative Process, Long Lasting Effect of Hyperbaric Oxygen Therapy in Retinitis Pigmentosa | Retinitis Pigmentosa | Procedure: hyperbaric oxygen therapy | Azienda Policlinico Umberto I | Not recruiting | 20 Years | 70 Years | Both | N/A | Italy | ||
| 70 | NCT00065455 | July 17, 2003 | 16 December 2017 | Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa | Pilot Study on the Effect of Vitamin A Supplementation on Cone Function in Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Vitamin A | National Eye Institute (NEI) | Not recruiting | 18 Years | N/A | All | 11 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 71 | NCT00346333 | July 2003 | 19 October 2017 | Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin A | Randomized Clinical Trial for Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Lutein;Dietary Supplement: Cornstarch control | National Eye Institute (NEI) | Not recruiting | 18 Years | 60 Years | All | 240 | Phase 3 | United States | |
| 72 | NCT00063765 | June 2003 | 19 February 2015 | Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye | A Phase I Study of NT-501-10 and NT-501-6A.02, Implants of Encapsulated Human NTC-210 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Patients With Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Ciliary Neurotrophic Factor Implant NT-501 | National Eye Institute (NEI) | Not recruiting | N/A | N/A | Both | 10 | Phase 1 | United States | |
| 73 | JPRN-UMIN000007895 | 2001/07/01 | 2 April 2019 | Effects of nilvadipine on the progression of visual field defects in patients with retinitis pigmentosa | retinitis pigmentosa | Treated group: oral administration of nilvadipine 4mg per day Control group: herenien, tocoferol or no medication as patients' requests | Department of Ophthalmology, Hirosaki University Graduate School of Medicine | Not Recruiting | 20years-old | 80years-old | Male and Female | 40 | Phase 2 | Japan | ||
| 74 | NCT00029289 | April 2001 | 19 February 2015 | Effects of Lutein in Retinitis Pigmentosa | Effects of Lutein in Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Lutein (10 or 30 mg/day) capsules | National Center for Complementary and Integrative Health (NCCIH) | Not recruiting | Phase 1/Phase 2 | United States | |||||
| 75 | NCT00000116 | May 1996 | 19 February 2015 | Randomized Trial for Retinitis Pigmentosa | Randomized Trial for Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Vitamin A;Drug: Nutritional Supplement | National Eye Institute (NEI) | Not recruiting | 18 Years | 56 Years | Both | Phase 3 | United States | ||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 76 | NCT00004827 | March 1996 | 7 April 2015 | Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: docosahexaenoic acid | Retina Foundation of the Southwest | Not recruiting | N/A | N/A | Male | 46 | N/A | |||
| 77 | NCT00000114 | May 1984 | 19 February 2015 | Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis Pigmentosa | Retinitis Pigmentosa | Drug: Vitamin E;Drug: Vitamin A | National Eye Institute (NEI) | Not recruiting | 18 Years | 49 Years | Both | Phase 3 | ||||
| 78 | JPRN-JapicCTI-132079 | 2 April 2019 | Phase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period | Phase 3 Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period | Retinitis Pigmentosa | Intervention name : UF-021(isopropyl unoprostone) Dosage And administration of the intervention : Eye drop Control intervention name : null | R-Tech Ueno, Ltd | 20 | 70 | BOTH | Phase 3 |